<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000757</url>
  </required_header>
  <id_info>
    <org_study_id>AVEG 003A</org_study_id>
    <secondary_id>10541</secondary_id>
    <nct_id>NCT00000757</nct_id>
  </id_info>
  <brief_title>A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160</brief_title>
  <official_title>A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Protein Sciences Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and immune response to 160 mcg HIV-1 recombinant envelope glycoprotein&#xD;
      gp160. To evaluate the duration of antibody response and its relationship to dose and&#xD;
      frequency of inoculation.&#xD;
&#xD;
      Evaluation of previous patients who received doses of 40 or 80 mcg gp160 vaccine indicate&#xD;
      that, although serum anti-gp160 antibody responses were detected, the level and duration of&#xD;
      those responses were limited. A preliminary observation suggests that weak functional&#xD;
      antibody responses may develop following the 18 month booster of 40 or 80 mcg; therefore, a&#xD;
      dose of gp160 vaccine having potentially greater immunogenicity is of particular interest.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of previous patients who received doses of 40 or 80 mcg gp160 vaccine indicate&#xD;
      that, although serum anti-gp160 antibody responses were detected, the level and duration of&#xD;
      those responses were limited. A preliminary observation suggests that weak functional&#xD;
      antibody responses may develop following the 18 month booster of 40 or 80 mcg; therefore, a&#xD;
      dose of gp160 vaccine having potentially greater immunogenicity is of particular interest.&#xD;
&#xD;
      Healthy volunteers are injected on days 0, 30, 180, and 365 with either 160 mcg gp160 vaccine&#xD;
      (20 volunteers) or an alum placebo preparation (10 volunteers).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">October 1992</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gp160 Vaccine (MicroGeneSys)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Subjects must have:&#xD;
&#xD;
          -  Normal history and physical exam.&#xD;
&#xD;
          -  Negative for HIV infection by ELISA and Western blot (i.e., no reactivity at gp160,&#xD;
             gp120, gp41, or p24).&#xD;
&#xD;
          -  T4 count &gt;= 800 cells/mm3.&#xD;
&#xD;
          -  Normal chest x-ray and urinalysis.&#xD;
&#xD;
          -  Negative hepatitis B surface antigen.&#xD;
&#xD;
          -  Negative HIV p24 antigen test.&#xD;
&#xD;
          -  Normal skin reactivity by Merieux test.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Subjects with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Positive PPD.&#xD;
&#xD;
          -  Syphilis, gonorrhea, or any other sexually transmitted diseases (including chlamydia&#xD;
             or pelvic inflammatory disease).&#xD;
&#xD;
        Subjects with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of immunodeficiency, chronic illness, or use of immunosuppressive medications.&#xD;
&#xD;
          -  Syphilis, gonorrhea, or any other sexually transmitted diseases (including chlamydia&#xD;
             or pelvic inflammatory disease) in the past 6 months.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Prior blood transfusions or cryoprecipitates within the past 6 months.&#xD;
&#xD;
        Identifiable high-risk behavior for HIV infection (as determined by prescreening questions&#xD;
        designed to identify risk factors for HIV infection), including:&#xD;
&#xD;
          -  Any history of IV drug use.&#xD;
&#xD;
          -  Syphilis, gonorrhea, or any other sexually transmitted diseases (including chlamydia&#xD;
             or pelvic inflammatory disease) in the past 6 months.&#xD;
&#xD;
          -  More than two sexual partners, or sexual contact with a high-risk partner, in the past&#xD;
             6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Belshe R</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Clements ML</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Couch R</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Dolin R</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Levine M</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Wright P</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>St. Louis Univ. School of Medicine AVEG</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Keefer MC, Wolff M, Gorse GJ, Graham BS, Corey L, Clements-Mann ML, Verani-Ketter N, Erb S, Smith CM, Belshe RB, Wagner LJ, McElrath MJ, Schwartz DH, Fast P. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses. 1997 Sep 20;13(14):1163-77. doi: 10.1089/aid.1997.13.1163.</citation>
    <PMID>9310283</PMID>
  </reference>
  <reference>
    <citation>Keefer MC, Graham BS, Belshe RB, Schwartz D, Corey L, Bolognesi DP, Stablein DM, Montefiori DC, McElrath MJ, Clements ML, et al. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network. AIDS Res Hum Retroviruses. 1994 Dec;10(12):1713-23. doi: 10.1089/aid.1994.10.1713.</citation>
    <PMID>7888231</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccines, Synthetic</keyword>
  <keyword>Vaccinia Virus</keyword>
  <keyword>HIV-1</keyword>
  <keyword>HIV Envelope Protein gp160</keyword>
  <keyword>AIDS Vaccines</keyword>
  <keyword>HIV Seronegativity</keyword>
  <keyword>HIV Preventive Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

